Moore Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Moore Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-104,333	Closed	-$3.26M	–	800
2025 Q4	$3.26M	Sell	104,333 -60,864	-37%	-$1.5M	0.05%	309
2025 Q3	$3.34M	Buy	+165,197	New	+$2.9M	0.05%	299
2020 Q2	–	Sell	-1,100,000	Closed	-$9.88M	–	295
2020 Q1	$9.88M	Buy	+1,100,000	New	+$11.3M	0.41%	59
2016 Q1	–	Sell	-31,994	Closed	-$2.1M	–	337
2015 Q4	$2.1M	Buy	+31,994	New	+$1.98M	0.07%	211
2015 Q1	–	Sell	-180,000	Closed	-$10.4M	–	464
2014 Q4	$10.4M	Buy	+180,000	New	+$10M	0.33%	85

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moore Capital Management's TEVA Position: Q1 2026 in Review

Moore Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 104,333 shares — an estimated $3.26M sold.

Moore Capital Management first reported a position in TEVA in Q4 2014 and held it in 5 quarters. The position peaked at $10.4M in Q4 2014. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Moore Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 104,333 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.26M.
Moore Capital Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Moore Capital Management's Teva Pharmaceuticals position peaked at $10.4M in Q4 2014.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.